Merck & Company Inc (MRK)

89.30
+0.20(+0.22%)
  • Volume:
    2,617
  • Bid/Ask:
    89.30/89.50
  • Day's Range:
    88.50 - 90.30

MRK Overview

Prev. Close
89.1
Day's Range
88.5-90.3
Revenue
-
Open
89.2
52 wk Range
60.33-94.8
EPS
-
Volume
2,617
Market Cap
226.59B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
5,448
P/E Ratio
-
Beta
-
1-Year Change
32.83%
Shares Outstanding
2,533,279,845
Next Earnings Date
Oct 27, 2022
What is your sentiment on Merck&Co?
or
Market is currently closed. Voting is open during market hours.

Merck & Company Inc News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade

Merck & Company Inc Analysis

Merck & Company Inc Company Profile

Merck & Company Inc Company Profile

Employees
67500
  • Type:Equity
  • Market:Germany
  • ISIN:US58933Y1055
  • WKN:A0YD8Q

Merck & Co., Inc. is a global health care company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through two segments: Pharmaceutical and Animal Health. The Company's Pharmaceutical segment includes human health pharmaceutical and vaccine products. Its human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations. The Animal Health segment develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesNeutralNeutralBuyStrong BuyStrong Buy
Technical IndicatorsSellSellBuyStrong BuyStrong Buy
SummaryNeutralNeutralBuyStrong BuyStrong Buy
  • Basically When trading your stocks, you have to be very defensive and aggressive at the same time. If you are not aggressive, you are not going to make money, and if you are not defensive, you are not going to keep the money. Encounter an exciting trading result with a live signals with DYLAN HUGHES on What's🔛App 👉 + 44 7456 - 325 - 620
    0
    • 🚀🚀🚀🚀🚀🚀🚀
      1
      • This will be 120+ soon
        4
        • why Mr. Zingone at 120+ soon ? any reason please ? if you can help me i will appreciate so much . Best Regards, Elon.
          0
        • you are in outer space
          0
        • help you need to figure it out on your own listening to mrons and thier baseless predictions how is that working for you
          0
      • ma e' sui massimi da sempre? che t.p. si puo' immaginare a questo punto ?
        2
        • 🚀🚀🚀🚀🚀🚀🚀🌜
          0
          • Good, even great reasults in first quater of 2022.Let's hope to go back to 86-87 territory
            0
            • The invention relates to stable formulations of antibodies against human programmed death receptor PD-1, or antigen binding fragments thereof and a PH20 variant or fragment thereof. The invention further provides methods for treating various cancers with formulations of the invention.
              0
              • The invention relates to stable formulations of antibodies against human programmed death receptor PD-1, or antigen binding fragments thereof and a PH20 variant or fragment thereof. The invention further provides methods for treating various cancers with formulations of the invention. In some embodiments of the methods of the invention, the formulations are administered to a subject by subcutaneous administration.
                0
                • The invention relates to stable formulations of antibodies against human programmed death receptor PD-1, or antigen binding fragments thereof and a PH20 variant or fragment thereof. The invention further provides methods for treating various cancers with formulations of the invention. In some embodiments of the methods of the invention, the formulations are administered to a subject by subcutaneous administration.
                  0
                  • It was 22 in 1995. Do the math and look at the products.
                    0